DXR Daxor Corporation
HealthcareAs of 2026-05-25
Valuation
View DetailsP/E (TTM)
4.91
PEG
0.06
P/B
1.19
P/S
362.98
EV/EBITDA
5.72
DCF Value
$-0.03
FCF Yield
0.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
-57.5%
Operating Margin
6174.2%
Net Margin
6105.3%
ROE
22.5%
ROA
19.9%
ROIC
20.2%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 null | $131.8K | $9.5M | $— |
| FY null | $503.4K | $9.2M | $— |
| Q2 null | $18.3K | $-369.7K | $— |
| Q4 null | $695.3K | $2.2M | $— |
Analyst Ratings
View AllConsensus
Buy
Target (Consensus)
$23.00
Target (Median)
$23.00
Target Range
$23.00 - $23.00
Trading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
Medical - Instruments & Supplies
Country
US
Exchange
—
Beta
0.29
Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee.